Abstraction Health

Inositol — Stack & Timing

Educational timing and stacking information based on how Inositol has been studied. Not a prescription. Not medical advice.

This is educational information only, not medical advice. Supplement needs vary by individual, health status, and existing conditions. Inositol should not be used as a substitute for medical treatment of PCOS, anxiety disorders, or OCD. Consult a qualified healthcare provider before starting any supplement regimen.

Stack & Timing Guidance

Educational summary based on how Inositol has been studied and commonly used.

🟡Moderate Evidence

Commonly studied timing

EveningWith food

Timing varies by intended use. For sleep: 900mg taken 30-60 minutes before bed. For PCOS or metabolic support: 4g/day split into two doses with meals (e.g., 2g at breakfast and 2g at dinner). For anxiety/panic (high-dose protocol): 12-18g split across 2-3 doses throughout the day. Taking with food may reduce GI side effects at higher doses.

Dose ranges used in studies

90018000 mg myo-inositol

Dose ranges vary widely by indication. PCOS/metabolic: typically 2-4g/day. Anxiety/panic research used 12-18g/day (a very high dose with significant GI side effects for many people). Sleep-context anecdotal use: ~900mg. No established regulatory UL. Products sold as powder (most economical for high-dose use) or capsule. For combined myo/d-chiro inositol products, look for the 40:1 ratio.

↑ These are ranges from research studies, not personal dosing recommendations. Discuss with a clinician.

Commonly paired with

Magnesium

Both have evidence in the anxiety and sleep space via different mechanisms — magnesium via GABA/NMDA modulation, inositol via IP3/serotonin receptor pathways. Commonly combined in low-dose evening stacks.

Note: No direct RCT of the combination; evidence is extrapolated from individual supplement trials.

Ashwagandha

Both are used in anxiety-related contexts; ashwagandha has cortisol-modulating evidence while inositol addresses serotonin and second-messenger signaling. Some practitioners combine them for broader anxiolytic coverage.

Note: The combination has not been directly tested in RCTs. Ashwagandha evidence for anxiety is rated moderate; inositol evidence is weak-to-moderate depending on dose.

Folate (methylfolate)

In PCOS context, inositol and folate are sometimes combined. Some research has examined the combination in PCOS management, with folate supporting one-carbon metabolism and inositol supporting insulin signaling.

Note: Combination has been studied in PCOS specifically; preliminary evidence suggests additive benefit though large RCTs are needed.

Safety & interactions

Generally well-tolerated at doses under 4g/day. At high doses (12-18g/day), GI side effects are common — nausea, bloating, and loose stools are reported by a significant minority of users and are dose-dependent. Starting at a lower dose and titrating up may improve tolerability. Do not use high-dose inositol in individuals with a personal or family history of bipolar disorder without guidance from a psychiatrist. Not intended to replace evidence-based psychiatric treatment for anxiety, OCD, or panic disorder.

Known interactions
  • Lithium: Theoretical interaction — inositol depletion is proposed as one mechanism of lithium's action; supplementing inositol could theoretically attenuate lithium's therapeutic effect in bipolar disorder
  • SSRIs in bipolar patients: Some concern that high-dose inositol may interact with serotonergic medications in the context of bipolar disorder, potentially affecting mood stability
  • Insulin and diabetes medications: Inositol affects insulin signaling pathways; may influence blood glucose — monitor if taking insulin or hypoglycemics
Contraindications

High-dose inositol (>4g/day) should be avoided in individuals with bipolar disorder without psychiatric supervision due to theoretical risk of triggering manic episodes. Use in pregnancy should be discussed with a qualified healthcare provider.

Evidence basis: Stack guidance informed by Unfer et al. (2017) systematic review on PCOS, Nordio & Basciani (2018) RCT on metabolic syndrome, and Palatnik et al. review on panic disorder. Dose ranges reflect the populations studied in available RCTs.